RKV Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, today announced that the Company has been invited to present a poster presentation at the sixth biennial Canadian Cancer Research Conference (CCRC), which is being held virtually November 8-11, 2021.

The CCRC brings together the cancer research community for an agenda spanning the oncology research spectrum and presents an opportunity for researchers, trainees, clinicians, decision-makers, and patients to hear the latest developments in Canadian cancer research and network across multiple research disciplines.

During the meeting, Rakovina Therapeutics researchers will present an update on lead optimization activities with the Company’s novel kt-3000 series. The kt-3000 series drug candidates combine potent inhibition of histone deacetylase (HDAC) and poly (ADP-ribose) polymerase (PARP) in a single molecule. PARP-inhibitors have recently become important in the treatment of certain cancers including BRCA-mutant breast, ovarian and prostate cancers. Rakovina Therapeutics is researching the kt-3000 series potential to overcome cancer cells’ development of resistance to PARP-inhibitor therapy.

Further information and registration details for the CCRC can be found at https://www.ccra-acrc.ca/conference/

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

Additional Information

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.

Contact:

Rakovina Therapeutics Inc.David HymanChief Financial OfficerEmail: info@rakovinatherapeutics.com	Investor Relations ContactIR@rakovinatherapeutics.com Media ContactMEDIA@rakovinatherapeutics.com